Added to YB: 2025-02-05
Pitch date: 2024-12-19
AVIR [bullish]
Atea Pharmaceuticals, Inc.
+35.9%
current return
Author Info
No bio for this author
Company Info
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Market Cap
$332.1M
Pitch Price
$3.12
Price Target
5.10 (+20%)
Dividend
N/A
EV/EBITDA
N/A
P/E
N/A
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Atea Pharmaceuticals, Inc. - $AVIR
AVIR: Strategic alternatives process underway. $483M cash (~1.75x FDMC), net-net EV -$205M. Expect sale at $3.80-5.10/share (22-63% upside) in months. Two activists emerged. COVID-19 candidate failed, HCV candidate met P2 endpoint. Risks: no attractive bid, prolonged process, negative HCV developments.
Read full article (4 min)